Annexin A5 in Patients With Severe COVID-19 Disease

Phase 2 Completed 18 enrolled London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's London Health Sciences Foundation · collab Ontario Ministry of Colleges and Universities · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, double-blind, placebo-controlled trial comparing 2 doses of SY-005 (recombinant human Annexin A5) to placebo in patients with severe coronavirus 2019 disease in a single hospital centre with 2 intensive care units

Timeline

Start: 2021-04-20
Primary completion: 2022-04-03
Completion: 2022-12-01

Publications

Tschirhart BJ, Lu X, Mokale Kognou AL, Martin CM, Slessarev M, Fraser DD, Leligdowicz A, Urquhart B, Feng Q. Pharmacokinetics of recombinant human annexin A5 (SY-005) in patients with severe COVID-19. Front Pharmacol. 2024 Jan 10;14:1299613. doi: 10.3389/fphar.2023.1299613. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	recombinant human annexin A5	Protein / enzyme biologic	50 ug/kg	Intravenous
Subject	recombinant human annexin A5	Protein / enzyme biologic	100 ug/kg	Intravenous

Annexin A5 in Patients With Severe COVID-19 Disease

Summary

Timeline

Publications

Drugs

Indications